1477 Results

People

  1. Motzer
    Motzer
  2. Hudis
    Hudis
  3. Aghajanian
    Aghajanian
  4. O'Reilly
    O'Reilly
  5. Kris
    Kris
  6. Scher
    Scher
  7. Panageas
    Panageas
  8. Saltz
    Saltz
  9. Schwartz
    Schwartz
  10. Kelsen
    Kelsen

Groups

  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)
  7. Epidemiology and Biostatistics (194)
  8. Biostatistics Service (169)
  9. Gastrointestinal Oncology Service (160)
  10. Population Sciences Research Program (158)
  1. "fatigue"
Formats
  1. Journal Article (1402)
  2. Review (38)
  3. Research Letter (13)
  4. Editorial (10)
  5. Conference Paper (5)
  6. Guidelines (4)
  7. Correspondence (3)
  8. Book Section (2)
Groups
  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)

More Groups

People
  1. Robert Motzer (85)
  2. Clifford Hudis (49)
  3. Carol Aghajanian (46)
  4. Eileen O'Reilly (46)
  5. Howard Scher (44)
  6. Mark Kris (44)

More People

Years
  1. 2025 (60)
  2. 2024 (132)
  3. 2023 (89)
  4. 2022 (46)
  5. 2021 (33)
  6. 2020 (85)

More Years

Publications
  1. Journal of Clinical Oncology (108)
  2. Clinical Cancer Research (82)
  3. Cancer (63)
  4. Lancet Oncology (50)
  5. Gynecologic Oncology (41)
  6. Annals of Oncology (37)

More Publications

Publishers
  1. Elsevier Inc. (244)
  2. Springer (133)
  3. American Society of Clinical Oncology (114)
  4. Elsevier Science, Inc. (108)
  5. Oxford University Press (101)
  6. American Association for Cancer Research (89)

More Publishers

Results (1477)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Atezolizumab with neoadjuvant anti-human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2-positive early breast cancer: Primary results of the randomized phase III IMpassion050 trial
    Journal Article

    Huober, J.; Barrios, C. H.; Niikura, N.; Jarząb, M.; Chang, Y. C.; Huggins-Puhalla, S. L.; Pedrini, J.; Zhukova, L.; Graupner, V.; Eiger, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors
    Journal Article

    Borazanci, E.; Schram, A. M.; Garralda, E.; Brana, I.; Vieito Villar, M.; Spreafico, A.; Oliva, M.; Lakhani, N. J.; Hoffman, K.; Hallett, R. M.; more...
    ESMO Open (2022)

    Fulltext@MSK | Save
  • Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors
    Journal Article

    Park, H.; Shapiro, G. I.; Gao, X.; Mahipal, A.; Starr, J.; Furqan, M.; Singh, P.; Ahrorov, A.; Gandhi, L.; Ghosh, A.; more...
    ESMO Open (2022)

    Fulltext@MSK | Save
  • Outcomes and toxicities after proton partial breast radiotherapy for early stage, hormone receptor positive breast cancer: 3-Year results of a phase II multi-center trial
    Journal Article

    Choi, J. I.; Prabhu, K.; Hartsell, W. F.; DeWees, T.; Sinesi, C.; Vargas, C.; Benda, R. K.; Cahlon, O.; Chang, A. L.
    Clinical and Translational Radiation Oncology (2022)

    Fulltext@MSK | Save
  • First-in-human phase I study of the OX40 agonist MOXR0916 in patients with advanced solid tumors
    Journal Article

    Kim, T. W.; Burris, H. A. 3rd; de Miguel Luken, M. J.; Pishvaian, M. J.; Bang, Y. J.; Gordon, M.; Awada, A.; Camidge, D. R.; Hodi, F. S.; McArthur, G. A.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Acupuncture versus massage for pain in patients living with advanced cancer: A protocol for the IMPACT randomised clinical trial
    Journal Article

    Romero, S. A. D.; Emard, N.; Baser, R. E.; Panageas, K.; MacLeod, J.; Walker, D.; Barton-Burke, M.; Liou, K.; Deng, G.; Farrar, J.; more...
    BMJ Open (2022)

    Fulltext@MSK | Save
  • Well-differentiated thyroid cancer: Who should get postoperative radiation?
    Journal Article

    Adilbay, D.; Yuan, A.; Romesser, P. B.; Wong, R. J.; Shah, J. P.; Shaha, A. R.; Tuttle, M. R.; Patel, S.; Lee, N. Y.; Ganly, I.
    Annals of Surgical Oncology (2022)

    Fulltext@MSK | Save
  • Predictors of chronic COVID-19 symptoms in a community-based cohort of adults
    Journal Article

    Silverberg, J. I.; Zyskind, I.; Naiditch, H.; Zimmerman, J.; Glatt, A. E.; Pinter, A.; Theel, E. S.; Joyner, M. J.; Hill, D. A.; Lieberman, M. R.; more...
    PLoS ONE (2022)

    Fulltext@MSK | Save
  • Telaglenastat plus everolimus in advanced renal cell carcinoma: A randomized, double-blinded, placebo-controlled, phase II ENTRATA trial
    Journal Article

    Lee, C. H.; Motzer, R.; Emamekhoo, H.; Matrana, M.; Percent, I.; Hsieh, J. J.; Hussain, A.; Vaishampayan, U.; Liu, S.; McCune, S.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Triplet therapy, transplantation, and maintenance until progression in myeloma
    Journal Article

    Richardson, P. G.; Jacobus, S. J.; Weller, E. A.; Hassoun, H.; Lonial, S.; Raje, N. S.; Medvedova, E.; McCarthy, P. L.; Libby, E. N.; Voorhees, P. M.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save